MA28240A1 - Combinaison de (a) { n-5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl-4-(3-pyridyl)-2-pyrimidine-amine et (b) au moins un inhibiteur de formation de l'hypusine et son utilisation - Google Patents

Combinaison de (a) { n-5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl-4-(3-pyridyl)-2-pyrimidine-amine et (b) au moins un inhibiteur de formation de l'hypusine et son utilisation

Info

Publication number
MA28240A1
MA28240A1 MA29141A MA29141A MA28240A1 MA 28240 A1 MA28240 A1 MA 28240A1 MA 29141 A MA29141 A MA 29141A MA 29141 A MA29141 A MA 29141A MA 28240 A1 MA28240 A1 MA 28240A1
Authority
MA
Morocco
Prior art keywords
methyl
hypusin
combination
benzoylamido
piperazino
Prior art date
Application number
MA29141A
Other languages
English (en)
Inventor
Tim H Bruemmendorf
Stefan Balabanov
Ulrike Hartmann
Winfried Kammer
Alfred Nordheim
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA28240A1 publication Critical patent/MA28240A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention porte sur une méthode de traitement s'appliquant à un animal à sang chaud, tel que l'être humain, atteint d'une maladie proliférative. Cette méthode consiste à administrer à l'animal une combinaison comprenant (a) N-{5-[4-(4-méthyl-pipérazino-méthyl)-benzoylamido]-2-méthylphényl}-4-(3-pyridyl)-2-pyrirnidine-amine et (b) au moins un inhibiteur de formation de l'hypusine. L'invention porte également sur une combinaison comprenant : (a) et (b) telle que définie ci-dessus et éventuellement au moins un excipient acceptable d'un point de vue pharmaceutique et destiné à être utilisé simultanément, séparément ou séquentiellement, notamment pour retarder l'évolution ou le traitement d'une maladie proliférative, et enfin sur l'utilisation d'au moins un inhibiteur de formation de l'hypusine dans la préparation d'un médicament en vue de retarder l'évolution ou le traitement de la leucémie, notamment la leucémie résistant à Imatinib.
MA29141A 2003-12-19 2006-06-26 Combinaison de (a) { n-5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl-4-(3-pyridyl)-2-pyrimidine-amine et (b) au moins un inhibiteur de formation de l'hypusine et son utilisation MA28240A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US53156303P 2003-12-19 2003-12-19

Publications (1)

Publication Number Publication Date
MA28240A1 true MA28240A1 (fr) 2006-10-02

Family

ID=34700180

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29141A MA28240A1 (fr) 2003-12-19 2006-06-26 Combinaison de (a) { n-5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl-4-(3-pyridyl)-2-pyrimidine-amine et (b) au moins un inhibiteur de formation de l'hypusine et son utilisation

Country Status (17)

Country Link
US (1) US20080139480A1 (fr)
EP (1) EP1696917A1 (fr)
JP (1) JP2007514699A (fr)
KR (1) KR20060125810A (fr)
CN (1) CN1889952A (fr)
AU (2) AU2004298761A1 (fr)
BR (1) BRPI0417759A (fr)
CA (1) CA2547196A1 (fr)
EC (1) ECSP066656A (fr)
IL (1) IL176070A0 (fr)
MA (1) MA28240A1 (fr)
MX (1) MXPA06006925A (fr)
NO (1) NO20063326L (fr)
RU (1) RU2006125741A (fr)
TN (1) TNSN06182A1 (fr)
WO (1) WO2005058320A1 (fr)
ZA (1) ZA200603904B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2197440B1 (fr) 2007-08-31 2012-12-26 Janssen Pharmaceutica, N.V. Combinaisons d'imazalil et d'hydroxypyridones
WO2009036753A2 (fr) * 2007-09-20 2009-03-26 Schebo Biotech Ag Nouveaux produits pharmaceutiques, procédés de fabrication de ceux-ci et utilisation de ceux-ci en thérapie médicale
US8575187B2 (en) 2008-02-06 2013-11-05 Janssen Pharmaceutica, Nv Combinations of anilinopyrimidines and pyrion compounds
CA2711762C (fr) 2008-02-06 2016-11-01 Jan Pieter Hendrik Bosselaers Combinaisons de phenylpyrroles et de composes pyrion
WO2010048712A1 (fr) * 2008-10-31 2010-05-06 University Health Network Ciclopirox et cytarabine pour le traitement de troubles leucémiques
JP6019015B2 (ja) * 2010-06-01 2016-11-02 ビオトヘルイク， インコーポレイテッド ６−シクロヘキシル−１−ヒドロキシ−４−メチル−２（１ｈ）−ピリドンを使用する血液悪性疾患の治療方法
MX2012013879A (es) * 2010-06-01 2013-04-03 Biotheryx Inc Derivados de hidroxipiridona, composiciones farmceuticas de los mismos y su uso terapeutico para tratar enfermedades proliferativas.
CN102917591B (zh) 2010-06-10 2014-07-23 詹森药业有限公司 嘧霉胺和单萜烯的组合
EP2587920B1 (fr) 2010-07-01 2016-08-10 Janssen Pharmaceutica, N.V. Combinaisons antimicrobiennes des composes de pyrion avec des polyéthylèneimines
CN103191110A (zh) * 2013-03-28 2013-07-10 中国科学院昆明植物研究所 环吡酮及环吡酮胺在制备防治黑色素瘤的药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8528983D0 (en) * 1985-11-25 1986-01-02 Ciba Geigy Ag Use of chelating agents
EP0227593A1 (fr) * 1985-11-25 1987-07-01 The Hospital For Sick Children Application d'agents chélatants
TW533205B (en) * 1996-06-25 2003-05-21 Novartis Ag Substituted 3,5-diphenyl-l,2,4-triazoles and their pharmaceutical composition
ES2331562T3 (es) * 2001-03-23 2010-01-08 Enzon, Inc. Profarmacos de agentes anticancerigenos que emplean acidos aromaticos sustituidos.
AU2003251875A1 (en) * 2002-07-15 2004-02-02 Combinatorx, Incorporated Combination therapy for the treatment of neoplasms

Also Published As

Publication number Publication date
CN1889952A (zh) 2007-01-03
NO20063326L (no) 2006-09-19
RU2006125741A (ru) 2008-01-27
EP1696917A1 (fr) 2006-09-06
ECSP066656A (es) 2006-10-25
KR20060125810A (ko) 2006-12-06
US20080139480A1 (en) 2008-06-12
BRPI0417759A (pt) 2007-04-10
TNSN06182A1 (en) 2007-11-15
AU2009201694A1 (en) 2009-05-28
AU2004298761A1 (en) 2005-06-30
JP2007514699A (ja) 2007-06-07
IL176070A0 (en) 2006-10-05
MXPA06006925A (es) 2006-08-23
CA2547196A1 (fr) 2005-06-30
ZA200603904B (en) 2007-09-26
WO2005058320A1 (fr) 2005-06-30

Similar Documents

Publication Publication Date Title
ECSP034823A (es) Combinación que comprende n-{5-[4-(4-metil-piperazino-metil)-benzoilamido]-2-metilfenil}-4-(3-piridil)-2-pirimidin-amina, y un agente quimioterapéutico
RU2003114752A (ru) Лечение желудочно-кишечных стромальных опухолей
JP2005502643A5 (fr)
ATE466580T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE468336T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE365733T1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
MA28240A1 (fr) Combinaison de (a) { n-5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl-4-(3-pyridyl)-2-pyrimidine-amine et (b) au moins un inhibiteur de formation de l'hypusine et son utilisation
DE69925024D1 (de) Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten
JP2003523325A5 (fr)
TWI265930B (en) N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
DE60323133D1 (de) Cyclohexylverbindungen als ccr5-antagonisten
ATE384724T1 (de) Cyclopropylverbindungen als ccr5 antagonisten
ATE450530T1 (de) Zusammensetzungen zur verwendung als protein- kinase-inhibitoren
MY128051A (en) Mesylate trihydrate salt of 5-(2-(4-(1, 2-benzisothiazol-3 -yl)-1-piperazinyl)ethyl)-6-chloro-1, 3-dihydro-2-(1h)-indol-2-one (=ziprasidone), its preparation and its use as dopamine d2 antagonist
BR0312873A (pt) 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il) pirimidin-2-ilamino)fenil] benzamida para tratamento de doenças associadas com ret cinase mutante
BG102892A (en) Mesylate dihydrated salts of 5-(2-4(1,2-benzisothiazol-3-yl)-1-piperazinyl)-athyl)-6-chloro-1,3 -dihydro-2(1h)-indol-on(=ciprazidon), their preparation and application as dopamine d2 antagonists
BG107468A (en) N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl] carboxamide inhibitors of cyclin dependent kinases
MY125768A (en) N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
JP2009532438A5 (fr)
DE602006017574D1 (de) Als protein-kinase-inhibitoren nutzbare benzimidazole
SE9903995D0 (sv) New combination
EP1266663A4 (fr) Inducteur de l'apoptose specifique a l'eosinophilie
SE9902935D0 (sv) Pharmaceutical compositions
NZ535611A (en) Pharmaceutical composition of a PDE4 or a PDE3/4 inhibitor and a histamine receptor antagonist
AR045330A1 (es) Forma de dosificacion oral, procedimiento para su preparacion y uso del compuesto 5-(4-(2-(n-metil-n- (2-piridil)amino)etoxi )bencil) tiazolidin-2,4-diona o una sal o solvato farmaceuticamente aceptable del mismo para prepararla